The research was led by professor Zhou Dawang and Deng Xianming of the School of Life Sciences, Xiamen University, and professor Yun Caihong of Peking University.
Zhou said they have discovered a drug, XMU-MP-1, which can promote repair and regeneration in the liver, intestines and skin, state-run Xinhua news agency reported.
In the future, the pills may do away the need for organ transplant or complex biomaterial and cell therapies, he said.
Zhou and his colleagues specifically targeted a critical signaling molecule in the Hippo pathway, which controls organ size.
Zhou said they have applied for a patent and are cooperating with pharmaceutical companies to produce the medicine.
The findings were published in the latest edition of Science Translational Medicine on August 17.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
